

ХРОНИЧНА МИЕЛОИДНА ЛЕВКЕМИЯ

ОБЗОРИ

REVIEWS

NEW APPROACHES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA

J. Raynov

Military Medical Academy - Sofia

Summary. *This review discusses non-transplant treatment options for patients with chronic myeloid leukemia (CML). CML is an example how a cytogenetic molecular disease can lead to important findings in the hematology. This knowledge has facilitated the development of targeted cancer-specific therapies. An example of this is the signal transduction inhibitor 571 (STI571), also known as Imatinib mesylate (Glivec, Novartis). Review discusses clinical results with interferon- α , imatinib mesylate, and the other active agents in CML: homoharringtonine, oral citarabine precursor YNK01, decitabine, troxacitabine, clofarabine, arsenic trioxide. Target-therapy with imatinib mesilate changed substantially the management of CML. At the present time, it is the best drug for newly diagnosed patients, unsuitable for initial treatment with allogeneic stem cell transplantation.*

Key words: *leukemia, myeloid, chronic/drug therapy; interferon alpha/therapeutic use; piperazines/therapeutic use; pyrimidines/therapeutic use (source: MeSH)*
